U.S. FDA considering lowering recommended age for Pfizer/BioNTech COVID-19 boosters

NEW YORK (Reuters) - A top U.S. Food and Drug Administration official said on Friday that the agency is considering lowering the recommended age for who should receive booster shots of the Pfizer/BioNTech COVID-19 vaccine to as young as 40 years old, based on data from Israel suggesting the vaccine's efficacy is waning.

Israeli scientists presented "data that seemed compelling in the 40 and up age range," Dr. Peter Marks, Director of the FDA's Center for Biologics Evaluation and Research said, speaking to the agency's Vaccines and Related Biological Products Advisory Committee.

(Reporting by Michael Erman, Editing by Franklin Paul)

You May Also Be Interested In

• Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
• Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
• FDA approves Regeneron's Pasatru for rare bone disorder FOP